DOI: https://doi.org/10.36347/sasjm.2024.v10i10.046

Pages: 1214-1228

Metastatic breast cancer is recognized as an incurable disease and whose management is palliative, but in recent years there has been an increase in the overall survival of patients with metastatic Her2 + breast cancer, this is thanks to the development new, particularly targeted therapies. Our study aims to assess the value of the double combination pertuzumab to the reference dual therapy (trastuzumab + chemotherapy) in patients with metastatic breast cancer and its impact on overall survival. This is a retrospective study spread over a period of 2 years (2018- 2019) carried out in the medical oncology department of the Moulay Ismail military hospital in Meknes.